Myasthenia gravis is a chronic autoimmune disease in which the immune system produces autoantibodies that bind to and block acetylcholine receptors at the neuromuscular junction, leading to progressive muscle weakness.
Which of the following therapeutic strategies would be an effective treatment for a patient with myasthenia gravis?
Monoclonal antibodies designed to specifically bind to and destroy the B-lymphocytes that produce the autoantibodies.
A vaccine containing purified acetylcholine receptors to stimulate active immunity against the receptor.
A course of broad-spectrum antibiotics to eliminate the bacterial pathogens causing neuromuscular degradation.
Therapeutic administration of cytokines that stimulate the clonal expansion of B-lymphocytes into plasma cells.
